Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering from What is Known As Long COVID (LC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID. Xiflam (n=10) or placebo (n=5) will be administered orally once a day (QD) for 12 weeks.
Epistemonikos ID: 2ea72d170d3fad9354b71918b6da1c4a215ab08c
First added on: Jun 01, 2024